CAREDX INC (CDNA) Stock Fundamental Analysis
NASDAQ:CDNA - US14167L1035 - Common Stock
13.66 USD
+0.55 (+4.2%)
13.8608 USD
+0.2 (+1.47%)
Overall CDNA gets a fundamental rating of 5 out of 10. We evaluated CDNA against 542 industry peers in the Biotechnology industry. CDNA has an average financial health and profitability rating. CDNA is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year CDNA was profitable.
In the past year CDNA had a positive cash flow from operations.
In the past 5 years CDNA reported 4 times negative net income.
In multiple years CDNA reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of CDNA (11.63%) is better than 94.28% of its industry peers.
CDNA has a Return On Equity of 15.79%. This is amongst the best in the industry. CDNA outperforms 94.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.63% | ||
| ROE | 15.79% | ||
| ROIC | N/A |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 15.16%, CDNA belongs to the best of the industry, outperforming 93.54% of the companies in the same industry.
CDNA has a better Gross Margin (66.90%) than 79.89% of its industry peers.
In the last couple of years the Gross Margin of CDNA has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 15.16% | ||
| GM | 66.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
2. Health
2.1 Basic Checks
CDNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CDNA has more shares outstanding than it did 1 year ago.
CDNA has more shares outstanding than it did 5 years ago.
CDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CDNA has an Altman-Z score of 2.52. This is not the best score and indicates that CDNA is in the grey zone with still only limited risk for bankruptcy at the moment.
CDNA has a better Altman-Z score (2.52) than 70.48% of its industry peers.
There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 2.52 |
ROIC/WACCN/A
WACC9.86%
2.3 Liquidity
A Current Ratio of 3.30 indicates that CDNA has no problem at all paying its short term obligations.
CDNA has a Current ratio of 3.30. This is in the lower half of the industry: CDNA underperforms 60.52% of its industry peers.
CDNA has a Quick Ratio of 3.00. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
CDNA has a Quick ratio of 3.00. This is in the lower half of the industry: CDNA underperforms 61.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.3 | ||
| Quick Ratio | 3 |
3. Growth
3.1 Past
CDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 492.31%, which is quite impressive.
The Earnings Per Share has been growing by 37.47% on average over the past years. This is a very strong growth
Looking at the last year, CDNA shows a quite strong growth in Revenue. The Revenue has grown by 14.72% in the last year.
Measured over the past years, CDNA shows a very strong growth in Revenue. The Revenue has been growing by 21.30% on average per year.
EPS 1Y (TTM)492.31%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%-60%
Revenue 1Y (TTM)14.72%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%-6.06%
3.2 Future
Based on estimates for the next years, CDNA will show a very strong growth in Earnings Per Share. The EPS will grow by 39.98% on average per year.
CDNA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.69% yearly.
EPS Next Y5.4%
EPS Next 2Y32.82%
EPS Next 3Y39.98%
EPS Next 5YN/A
Revenue Next Year11.63%
Revenue Next 2Y12.23%
Revenue Next 3Y11.69%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
CDNA is valuated quite expensively with a Price/Earnings ratio of 26.78.
Based on the Price/Earnings ratio, CDNA is valued cheaper than 93.36% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.13, CDNA is valued at the same level.
Based on the Price/Forward Earnings ratio of 14.34, the valuation of CDNA can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CDNA indicates a rather cheap valuation: CDNA is cheaper than 95.02% of the companies listed in the same industry.
CDNA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.76.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.78 | ||
| Fwd PE | 14.34 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, CDNA is valued cheaper than 92.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.22 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CDNA's earnings are expected to grow with 39.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.96
PEG (5Y)0.71
EPS Next 2Y32.82%
EPS Next 3Y39.98%
5. Dividend
5.1 Amount
CDNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.66
+0.55 (+4.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.78%
Inst Owner Change-2.22%
Ins Owners2.37%
Ins Owner Change4.95%
Market Cap727.12M
Analysts81.43
Price Target22.95 (68.01%)
Short Float %11.49%
Short Ratio3.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.98%
Min EPS beat(2)-18.08%
Max EPS beat(2)36.04%
EPS beat(4)3
Avg EPS beat(4)331.94%
Min EPS beat(4)-18.08%
Max EPS beat(4)1272.55%
EPS beat(8)7
Avg EPS beat(8)222.06%
EPS beat(12)11
Avg EPS beat(12)158.17%
EPS beat(16)12
Avg EPS beat(16)125.68%
Revenue beat(2)0
Avg Revenue beat(2)-3.92%
Min Revenue beat(2)-6.22%
Max Revenue beat(2)-1.61%
Revenue beat(4)2
Avg Revenue beat(4)-1.5%
Min Revenue beat(4)-6.22%
Max Revenue beat(4)0.91%
Revenue beat(8)6
Avg Revenue beat(8)8.02%
Revenue beat(12)7
Avg Revenue beat(12)5.22%
Revenue beat(16)8
Avg Revenue beat(16)3.59%
PT rev (1m)-23.91%
PT rev (3m)-21.4%
EPS NQ rev (1m)-2.47%
EPS NQ rev (3m)-15.42%
EPS NY rev (1m)-6.97%
EPS NY rev (3m)-7.49%
Revenue NQ rev (1m)1.13%
Revenue NQ rev (3m)0.69%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)-0.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.78 | ||
| Fwd PE | 14.34 | ||
| P/S | 2.13 | ||
| P/FCF | 61.22 | ||
| P/OCF | 41.03 | ||
| P/B | 2.22 | ||
| P/tB | 2.9 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.51
EY3.73%
EPS(NY)0.95
Fwd EY6.97%
FCF(TTM)0.22
FCFY1.63%
OCF(TTM)0.33
OCFY2.44%
SpS6.4
BVpS6.15
TBVpS4.72
PEG (NY)4.96
PEG (5Y)0.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.63% | ||
| ROE | 15.79% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 15.16% | ||
| GM | 66.9% | ||
| FCFM | 3.49% |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
F-Score7
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 41.29% | ||
| Cap/Sales | 1.71% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 22.98% | ||
| Current Ratio | 3.3 | ||
| Quick Ratio | 3 | ||
| Altman-Z | 2.52 |
F-Score7
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)106.55%
Cap/Depr(5y)139.53%
Cap/Sales(3y)4.27%
Cap/Sales(5y)5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)492.31%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%-60%
EPS Next Y5.4%
EPS Next 2Y32.82%
EPS Next 3Y39.98%
EPS Next 5YN/A
Revenue 1Y (TTM)14.72%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%-6.06%
Revenue Next Year11.63%
Revenue Next 2Y12.23%
Revenue Next 3Y11.69%
Revenue Next 5YN/A
EBIT growth 1Y35.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year119.14%
EBIT Next 3Y78.59%
EBIT Next 5YN/A
FCF growth 1Y185.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6229.29%
OCF growth 3YN/A
OCF growth 5YN/A